June 1st, 2020
Sema4 to Deliver High Capacity COVID-19 Testing in Partnership with the State of Connecticut
Sema4 will provide viral and antibody testing, along with a more comprehensive end-to-end digital solution when needed, for state employees, first responders, long-term care facilities, and primary care facilities in Connecticut.
STAMFORD, CT — June 1, 2020 — Sema4, a patient-centered health intelligence company, today announced a formal partnership with the State of Connecticut to be a COVID-19 testing provider for Connecticut residents. Sema4 will now provide additional testing to state employees, first responders, residents of long-term care facilities, and patients requiring care at primary care facilities, among others.
Sema4 is expanding its current COVID-19 viral testing capacity to 10,000 tests per day in early June. Sema4 will also offer antibody testing to identify people who have already been exposed to the SARS-CoV-2 virus and have mounted an immune response, with the ability to process 5,000 tests per day by the end of June. To aid employers in managing back-to-work programs when needed, Sema4 will provide an even more complete, end-to-end digital solution for those ordering and receiving these tests, including portals for registering employees, tracking samples, and reporting results to providers and patients/employees, and to the State.
A more complete end-to-end digital solution and increased viral testing capacity, coupled with the introduction of antibody testing, builds upon the steps that Sema4 has already taken to help combat COVID-19 in Connecticut. Since April, Sema4 has been collaborating with the State and has performed thousands of COVID-19 viral tests in its Branford, Connecticut laboratory for approximately 30 Connecticut-based health care facilities.
“Sema4 is playing a critical role in supporting the state with testing capacity,” said Lieutenant Colonel Christopher Chabot, leader of the Connecticut State COVID testing program. “We are very fortunate to have Sema4 as a partner with industry-leading testing experience, state-of-the-art digital tools and analysis, outstanding clinical expertise, and the labs to be able to ramp up COVID-19 testing quickly. Our partnership with Sema4 will make a significant difference in keeping many of our residents safe, including numerous people that are particularly vulnerable to infection.”
Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, added: “We are proud that Connecticut has selected us as a partner to fight the coronavirus pandemic. As a health intelligence company, we will fully leverage our technical expertise to deliver a state-of-the-art digital solution for the ordering, tracking, analysis and viewing of test results for providers and patients, in delivering rapid and accurate COVID-19 testing. Our team is working relentlessly to provide expanded viral and antibody testing to support state employees, first responders, and all Connecticut residents who need testing during this public health crisis. We are also engaging with large employers in the state to support their efforts to re-open offices by offering our digital tools and testing to support safe and healthy workplace environments.”
Sema4, which delivers advanced genomic solutions to hundreds of thousands of patients every year to support women’s health and precision oncology care, is actively scaling up its Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited laboratory in Branford, Connecticut to expand COVID-19 testing capacity. Sema4 accepts saliva, nasal swab, and oral swab samples, which are currently collected by a healthcare provider or at an authorized collection site. Sema4 will also soon be accepting saliva collected at home (FDA Emergency Use Authorization (EUA)-submitted). Testing is offered with no out-of-pocket cost to Connecticut residents.
The COVID-19 viral tests used by Sema4 are manufactured by PerkinElmer and the antibody tests are run on the Abbott Alinity™ system. Both tests have been validated in accordance with the FDA’s Emergency Use Authorization, and achieve the highest levels of sensitivity and specificity that have been demonstrated for these types of COVID-19 tests. Results are returned within approximately 24 hours of receiving the sample for the viral test and within around 48 hours for the antibody test.
For more information, please visit https://sema4.com/covid19-testing
Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.